Denise Wilburn
Family · Jeffersonville, INNPI 1417984758
Payments from drug & device makers
Across 226 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Indivior Inc.$294
- Amgen$255
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$238
- Vanda Pharmaceuticals Inc.$236
- Currax Pharmaceuticals LLC$194
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 85 | $1,223 |
| Indivior Inc. | 13 | $294 |
| Amgen | 17 | $255 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $238 |
| Vanda Pharmaceuticals Inc. | 10 | $236 |
| Currax Pharmaceuticals LLC | 14 | $194 |
| Alkermes, Inc. | 7 | $146 |
| AstraZeneca | 6 | $133 |
| USWM, LLC | 6 | $116 |
| Teva Pharmaceuticals USA, Inc. | 5 | $116 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Novartis | 6 | $81 |
| GSK | 5 | $77 |
| Lundbeck LLC | 4 | $74 |
| Averitas Pharma Inc. | 3 | $61 |
| Johnson & Johnson | 2 | $41 |
| Lilly USA, LLC | 3 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 1 | $37 |
| Novo Nordisk | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Bioxcel Therapeutics, Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $18 |
| Cipher Pharmaceuticals US LLC | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
| Tris Pharma Inc | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$3,776 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $75,349 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $43,757 |
| EliquisApixaban | 52 | $42,012 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 261 | $16,329 |
| JardianceEmpagliflozin | 20 | $14,656 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $9,056 |
| Gabapentin | 237 | $2,274 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $2,015 |
| Hydroxyzine Hcl | 86 | $1,601 |
| Ondansetron OdtOndansetron | 13 | $1,516 |
| Potassium Chloride | 77 | $1,125 |
| Levothyroxine Sodium | 124 | $1,061 |
| Theophylline ErTheophylline Anhydrous | 24 | $1,014 |
| Atorvastatin Calcium | 286 | $995 |
| Lidocaine | 17 | $899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $34 | $75,34976 claims |
| GSKTrelegy Ellipta | $77 | $43,75753 claims |
| AstraZenecaBreztri Aerosphere | $133 | $9,05612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.
Other family in Jeffersonville
- Rhonda StameyJeffersonville$28K
- Michelle VissingJeffersonville$18K
- Stacy GarciaJeffersonville$17K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.